Orthocell Limited announced that as part of its Board renewal program and following the appointment of the Hon Kim Beazley AC to the Board, Mr. Matthew Callahan, has resigned from the Board. Following Kim's appointment and the resignation of Matthew Callahan, the Orthocell Board has five Directors comprising four Non-Executive Directors and one Executive Director. With an experienced Board and Management Team, market leading products and strong balance sheet, Orthocell is well positioned to grow product sales alongside its distribution partners, BioHorizons and Device Technologies ­ which includes, as a priority, executing its US market access program and commercialisation strategy for its breakthrough nerve repair medical device, Remplir.

The aforementioned Board change is effective from 5.00 pm, 15 January 2024.